CLL/SLL care has been changing rapidly over the past several years.
Doctors Hallek and Al-Sawaf are among some of the very best to take on the task of documenting the latest changes that have been occurring in this lengthy encyclopedic overview that is full of solid data and historical references.
It was published for physicians in the American Journal of Hematology, and while it was not originally intended for patients, the information is free and accessible to all. Be prepared. The PDF version is 27 pages long!
It details several therapies such as ofatumumab, alemtuzumab, checkpoint inhibitors, lenalidomide, and PI3K inhibitors that are only now used in rare circumstances for CLL/SLL.
But it also covers all of the more commonly used medications, drugs that are in the development pipeline, and many exciting combination therapies.
It is an excellent overview if you have the time, want to do a deep dive, and have a strong fundamental understanding of the medical and scientific jargon.
It is long, very detailed, and full of excellent references. Even if one reads only a few of the pearls of wisdom from the sections relevant to their journey, it might help inform future treatment choices. And we all know that: Smart Patients Get Smart Care™.
Stay strong. We are all in this together.
Brian Koffman, MDCM (retired), MS Ed (he, him, his)
Co-Founder, Executive VP, and Chief Medical Officer, CLL Society, Inc.